Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

(2019) Nancy Y. Yu et al.   JAMA Oncology

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

(2018) Linda S Lindström et al.   JNCI-Journal of the National Cancer Institute

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

(2018) Linda S Lindström et al.   JNCI-Journal of the National Cancer Institute

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

(2017) Laura J. Esserman et al.   JAMA Oncology

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

(2016) Anna Nordenskjöld et al.   BREAST CANCER RESEARCH AND TREATMENT

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

“Score the Core” Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring

(2015) Jesse A. Engelberg et al.   HUMAN PATHOLOGY

Review of 103 Swedish Healthcare Quality Registries

(2014) L. Emilsson et al.   JOURNAL OF INTERNAL MEDICINE

Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer

(2013) X. H.- F. Zhang et al.   CLINICAL CANCER RESEARCH

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

(2011) P-L Jerevall et al.   BRITISH JOURNAL OF CANCER

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

(2011) Z. Bago-Horvath et al.   CLINICAL CANCER RESEARCH

The completeness of the Swedish Cancer Register – a sample survey for year 1998

(2008) Lotti Barlow et al.   ACTA ONCOLOGICA

Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients

(2008) R. Stuart-Harris et al.   BREAST

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY